Published in Clin Pharmacol on July 24, 2013
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes (2004) 3.95
Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 3.35
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci (2000) 3.10
Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 2.53
The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain (2008) 2.48
Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci (1992) 2.01
Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health (2005) 1.95
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet (2002) 1.69
Pharmacotherapy for breakthrough cancer pain. Drugs (2012) 1.69
Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage (2000) 1.59
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.39
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain (2006) 1.38
A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician (2012) 1.24
Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst (1998) 1.20
Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage (2010) 1.18
Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther (1988) 1.15
Adult cancer pain. J Natl Compr Canc Netw (2010) 1.11
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin (2009) 1.05
Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother (2011) 0.99
Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol (2010) 0.93
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol (2009) 0.93
Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin (2011) 0.90
Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care (2011) 0.89
The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med (2003) 0.86
Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin (2012) 0.86
The management of breakthrough cancer pain. Br J Nurs (2011) 0.86
Breakthrough cancer pain - still a challenge. J Pain Res (2012) 0.85
Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage (2010) 0.83
Ensuring safe access to medication for palliative care while preventing prescription drug abuse: innovations for American inner cities, rural areas, and communities overwhelmed by addiction. Risk Manag Healthc Policy (2011) 0.83
Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig (2011) 0.82
Intranasal fentanyl in the treatment of acute pain--a systematic review. Acta Anaesthesiol Scand (2012) 0.81
Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer. Int J Pharm (1999) 0.81
Assessing the impact of breakthrough cancer pain. Br J Nurs (2011) 0.81
Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery. AAPS J (2008) 0.80
Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Expert Opin Pharmacother (2012) 0.79
Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration. J Opioid Manag (2011) 0.79
Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. Clin Drug Investig (2013) 0.78
A review of the pharmacokinetic profile of transmucosal fentanyl formulations. Curr Med Res Opin (2012) 0.78
Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. Clin Ther (2013) 0.77
The sugar-loaded fentanyl lollipop (Actiq) and the risk for tooth decay. Gen Dent (2011) 0.76